Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Etomoxir (sodium salt)

Etomoxir ((R) - (+) -Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig[1].

Product Specifications

CAS Number

[828934-41-4]

Product Name Alternative

(R) - (+) -Etomoxir (sodium salt)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/_R_-__addition__-Etomoxir-sodium-salt.html

Purity

99.62

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(OCCCCCC[C@@]2(CO2)C(O[Na])=O)C=C1

Molecular Formula

C15H18ClNaO4

Molecular Weight

320.74

Precautions

H302, H315, H319, H335

References & Citations

[1]Roddy S O'Connor, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.Sci Rep. 2018 Apr 19;8 (1) :6289.|[2]Fred Y Xu, et al.Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells.J Lipid Res. 2003 Feb;44 (2) :415-23.|[3]Jun Li, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus.Sci Rep. 2015 Jul 31;5:12724.|[4]Joost J F P Luiken, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.Biochem J. 2009 Apr 15;419 (2) :447-55.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, protect from light, stored under nitrogen)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Am J Physiol Cell Physiol. 2025 Mar 1;328 (3) :C776-C790.|Am J Physiol Gastrointest Liver Physiol. 2025 Jun 1;328 (6) :G663-G676.|Antimicrob Agents Chemother. 2018 Apr 26;62 (5) . pii: e01659-17. |Cancer Lett. 2024 Jun 18:217068.|Cell Death Dis. 2022 Mar 11;13 (3) :229.|Cell Metab. 2022 Nov 1;34 (11) :1843-1859.e11.|Cell Rep. 2019 Apr 2;27 (1) :226-237.e4.|Cell Stem Cell. 2025 Dec 4;32 (12) :1849-1868.e15.|Dev Cell. 2025 Apr 18:S1534-5807 (25) 00206-0.|J Invest Dermatol. 2023 Oct;143 (10) :1993-2006.e10.|Life Sci. 2024 Aug 1:350:122763.|Lipids Health Dis. 2024 Feb 3;23 (1) :37.|Mol Cell. 2020 Oct 1;80 (1) :43-58.e7.|Mol Cell. 2022 Aug 18;82 (16) :3030-3044.e8.|Redox Biol. 2018 Jul;17:180-191.|Research Square Preprint. 2023 Aug 1.|Acta Biomater. 2022 Sep 15:150:83-95.|Acta Pharm Sin B. 2024 Nov 7.|Acta Pharmacol Sin. 2025 May 20.|Adv Sci (Weinh) . 2024 Nov 26:e2411559.|Adv Sci (Weinh) . 2025 Nov 6:e07384.|Aging Cell. 2024 Aug;23 (8) :e14184.|Ann Med. 2025 Dec;57 (1) :2497112.|Arterioscler Thromb Vasc Biol. 2025 Aug 21.|Autophagy. 2025 Jan;21 (1) :80-101.|Biochem Biophys Res Commun. 2017 Feb 5;483 (2) :860-866.|Biochem Biophys Res Commun. 2021 Oct 8:583:135-141.|Biochim Biophys Acta Mol Basis Dis. 2024 Jun 25:167314.|Biochim Biophys Acta Mol Basis Dis. 2025 May 24:167919.|bioRxiv. 2021 Mar 8.|bioRxiv. 2023 Apr 17.|bioRxiv. 2023 Nov 17.|bioRxiv. 2025 April 10.|bioRxiv. 2025 May 15.|Brain. 2024 Aug 28:awae270.|Cancer Cell Int. 2023 May 9;23 (1) :87.|Cancer Cell Int. 2025 May 14;25 (1) :176.|Cancer Cell. 2025 Jun 9;43 (6) :1108-1124.e11.|Cancer Res. 2023 Aug 1;83 (15) :2461-2470.|Cell Biol Int. 2024 Sep;48 (9) :1378-1391.|Cell Death Dis. 2023 Feb 15;14 (2) :125.|Cell Death Dis. 2023 Oct 6;14 (10) :653.|Cell Death Dis. 2025 Apr 14;16 (1) :291.|Cell Death Discov. 2024 May 1;10 (1) :207.|Cell Metab. 2023 Dec 5;35 (12) :2136-2152.e9.|Cell Metab. 2024 May 7;36 (5) :969-983.e10.|Cell Mol Gastroenterol Hepatol. 2025 May 21:101539.|Cell Physiol Biochem. 2018;48 (6) :2318-2336. |Cell Prolif. 2021 Nov;54 (11) :e13134.|Cell Rep Med. 2024 May 29:101592.|Cell Rep. 2021 Sep 7;36 (10) :109659.|Cell Rep. 2024 Feb 27;43 (2) :113739.|Cell Signal. 2025 Jan 26:111627.|Clin Mol Hepatol. 2024 May 10.|Clin Transl Med. 2022 Sep;12 (9) :e1061.|Clin Transl Oncol. 2025 Jun;27 (6) :2557-2567.|Commun Biol. 2022 Dec 7;5 (1) :1340.|Engineering. 2024 Sep 6.|Eur J Med Res. 2025 Jan 17;30 (1) :35.|FASEB J. 2025 Mar 15;39 (5) :e70439.|Fish Shellfish Immunol. 2024 Aug 12:109829.|Food Chem Toxicol. 2022 Nov:169:113450.|Free Radic Biol Med. 2022 Sep:190:94-104.|Free Radical Bio Med. 2019 Sep:141:372-382.|Front Biosci (Landmark Ed) . 2024 Feb 6;29 (2) :66.|Front Immunol. 2022 Mar 10;13:771732.|Front Oncol. 2021 Apr 22:11:665763.|Front Oncol. 2021 Apr 6.|Front Pharmacol. 2022 May 16;13:848957.|Hepatology. 2022 Dec;76 (6) :1617-1633.|Infect Genet Evol. 2020 Nov;85:104552.|Int J Biol Sci. 2021 Oct 11;17 (15) :4207-4222.|Int J Biol Sci. 2022 Mar 14;18 (6) :2484-2496.|Int J Biol Sci. 2025 Jan 1;21 (2) :725-744.|J Agric Food Chem. 2024 Jun 12;72 (23) :13039-13053.|J Biol Chem. 2024 Jul 11:107549.|J Biomed Mater Res A. 2022 Aug;110 (8) :1448-1459.|J Cell Biol. 2022 Dec 5;221 (12) :e202207022.|J Cell Sci. 2022 Aug 1;135 (15) :jcs259090.|J Immunother Cancer. 2025 Oct 23;13 (10) :e012162.|J Invest Dermatol. 2023 Oct;143 (10) :1993-2006.e10.|J Orthop Surg Res. 2023 May 26;18 (1) :386.|Johns Hopkins University. 2025 Sep.|Med Oncol. 2025 Jul 14;42 (8) :332.|Mol Cell. 2024 Jun 21:S1097-2765 (24) 00477-5.|Mol Med. 2025 Oct 9;31 (1) :310.|Mol Metab. 2024 Jun:84:101953.|Nat Commun. 2021 Jun 16;12 (1) :3660.|Nat Commun. 2022 Jun 17;13 (1) :3486.|Nat Commun. 2024 Aug 3;15 (1) :6587.|Nat Commun. 2024 May 7;15 (1) :3805.|Nat Commun. 2025 Feb 1;16 (1) :1241.|Nat Commun. 2025 Jan 2;16 (1) :212.|Nat Commun. 2025 May 15;16 (1) :4502.|Nat Genet. 2025 Mar;57 (3) :680-693.|Nat Metab. 2022 Oct;4 (10) :1287-1305.|Nat Metab. 2025 Sep 30.|Neoplasia. 2025 Feb 3:61:101125.|Oncogene. 2025 Sep;44 (34) :3096-3112.|Oncol Rep. 2023 Jul;50 (1) :138.|Oncol Rep. 2023 Jul;50 (1) :141.|Oncotarget. 2016 Oct 11;7 (41) :67071-67086.|Pharmacol Res. 2021 Oct:172:105796.|PLoS Biol. 2025 Nov 24;23 (11) :e3003490.|Proc Natl Acad Sci U S A. 2021 Nov 16;118 (46) :e2105950118.|Redox Biol. 2018 Oct;19:412-428. |Redox Biol. 2021 Oct:46:102082.|Research (Wash D C) . 2023:6:0087.|Research Square Preprint. 2020 Sep.|Research Square Preprint. 2022 Feb.|Rheumatology (Oxford) . 2024 Jun 5:keae320.|Sci Adv. 2023 Apr 14;9 (15) :eadf8522.|Sci Adv. 2025 Aug 29;11 (35) :eadu6271.|Sci Immunol. 2023 Sep 29;8 (87) :eabq2424.|Sci Rep. 2024 Jan 18;14 (1) :1600.|Sci Rep. 2025 Aug 20;15 (1) :30552.|SSRN. 6 Dec 2022.|Stem Cell Res Ther. 2024 Sep 27;15 (1) :328.|Theranostics. 2020 May 16;10 (14) :6483-6499. |Universidade de São Paulo. Ribeirão Preto, 2021.|Vet Microbiol. 2024 Jan:288:109932.

Available Sizes

More Discoveries

Explore Other Products

Browse additional items from our catalog

TRIM5, Control Peptide (Tripartite Motif-containing Protein 5, RING Finger Protein 88, RNF88)
147561 100 µg

TRIM5, Control Peptide (Tripartite Motif-containing Protein 5, RING Finger Protein 88, RNF88)

Sign In for Pricing
View Details
GDF6 Protein Vector (Mouse) (pPM-C-HA)
PV181640 500 ng

GDF6 Protein Vector (Mouse) (pPM-C-HA)

Sign In for Pricing
View Details
Rab18 (NM_181070) Mouse Tagged ORF Clone Lentiviral Particle
MR202181L4V 200 µL

Rab18 (NM_181070) Mouse Tagged ORF Clone Lentiviral Particle

Sign In for Pricing
View Details
CD55 Rabbit Monoclonal Antibody (Detector)
E56PA0471 100 µL

CD55 Rabbit Monoclonal Antibody (Detector)

Sign In for Pricing
View Details
VPS45, CT (VPS45, VPS45A, VPS45B, Vacuolar protein sorting-associated protein 45) (MaxLight 405) discontinued
043777-ML405 100 µL

VPS45, CT (VPS45, VPS45A, VPS45B, Vacuolar protein sorting-associated protein 45) (MaxLight 405) discontinued

Sign In for Pricing
View Details
Lentiviral human VAT1L shRNA (UAS) - Lentiviral human VAT1L shRNA (UAS, iRFP) (25)
GTR15307913 1 Vial

Lentiviral human VAT1L shRNA (UAS) - Lentiviral human VAT1L shRNA (UAS, iRFP) (25)

Sign In for Pricing
View Details